Rx Omega-3 No Better Than Corn Oil for Preventing CV Events
Astra-Zeneca’s Epanova—a highly processed carboxylic acid form of EPA and DHA– failed to deliver the expected reduction in major cardiovascular events observed during 2019’s REDUCE-IT trial using the fish oil-based Vascepa EPA. The just-published multicenter STRENGTH trial ( (STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia) randomized 13,078 high-risk patients […]